HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Amrubicin

HCID 3035016
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
110267-81-7
Standard SMILES
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
InChIKey
VJZITPJGSQKZMX-XDPRQOKASA-N
Molecular formula
C25H25NO9
Average molar mass
483.5 g/mol
Monoisotopic mass
483.15293138

Overview

Amrubicin is a synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol. It has a role as a topoisomerase II inhibitor, an antineoplastic agent and a prodrug. It is a quinone, an anthracycline antibiotic, a primary amino compound, a member of tetracenes and a methyl ketone.

Names & identifiers

Preferred name
Amrubicin
IUPAC
(7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
English name
Amrubicin
Molecular formula
C25H25NO9
Molecular weight
483.47

Names & synonyms

Amrubicin110267-81-7amrubicinaamrubicineamrubicinum93N13LB4Z2CHEBI:135779DTXSID30869526RefChem:557927DTXCID00817498L01DB10(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
Show more names
CS-1168Amurubicin(7S)-9β-Amino-9-acetyl-7β-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy--D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione5,12-Naphthacenedione,9-acetyl-9-aMino-7-(2-deoxy-b-D-erythro-pentopyranosyl)oxy-7,8,9,10-tetrahydro-6,11-dihydroxy-,(7S,9S)-(7S,9S)-9-Amino-9-acetyl-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione(7S,9S)-9-Acetyl-9-amino-7-(2-deoxy-β-D-erythro-pentopyranosyloxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydro-5,12-naphthacenedione5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)-

Properties

Computed structural properties

XLogP
0.9
Topological polar surface area
177 Ų
Hydrogen bond donors
5
Hydrogen bond acceptors
10
Rotatable bonds
3
Heavy atoms
35
Formal charge
0
Complexity
881

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Solubilitynot soluble in water, but soluble in DMSO
Melting Point172-174

Physicochemical properties

Melting point
172 · 172-1740C
alpha
20 · D20 +119° (c = 0.02 in CHCl3)
Boiling point
717.8 · 717.8±60.0 °C(Predicted)
Density
1.6 · 1.60±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
solubility
16.45 mg/mL · >16.45mg/mL in DMSO
form
Powder
pka
7.83 · 7.83±0.60(Predicted)
color
Pink to red
FDA UNII
93 N13LB4Z2 · 93N13LB4Z2

Chemistry & industry

Pharmacology

ATC Code · 2 items

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding · 1 item

A study was performed on the plasma protein binding of amrubicin in both patients with hepatic impairment and those with normal liver function. In those with liver impairment, the plasma protein binding was found to be 91.3–97.1% and in those with normal hepatic function, 82.0–85.3%.

Pharmacodynamics · 1 item

The _anthracycline glycoside_ group of antibiotics, which includes amrubicin, represent a group of potent anticancer agents with potent activity against both solid tumors and hematological malignancies. They are the principal subjects of a large number of studies for the treatment of adult and childhood neoplastic diseases. Amrubicin is a 9-aminoanthracycline derivative and promotes cell growth inhibition by stabilizing protein – DNA complexes followed by double-stranded DNA breaks, which are mediated by topoisomerase-II enzyme. Anthracyclines have been observed to have a variety molecular effects (for example, DNA intercalation, inhibition of topoisomerase II, and stabilization of topoisomerase IIα cleavable complexes). Amrubicin shows decreased DNA intercalation when compared with doxorubicin. The decreased DNA interaction likely influences the intracellular distribution because amrubicin and its metabolite, _amrubicinol_. Amrubicin showed 20% distribution into the nucleus of P388 cells compared with the 80% nuclear distribution shown by doxorubicin (another anthracycline drug). The cell growth inhibitory effects of amrubicin appear to be mainly due to the inhibition of topoisomerase II.

Mechanism of Action · 1 item

As an anthracycline, amrubicin has antimitotic and cytotoxic activity through a variety of mechanisms of action. Amrubicin is found to form complexes with DNA via intercalation between base pairs, and it inhibits topoisomerase II enzyme activity by stabilizing the DNA-topoisomerase II complex, which prevents the re-ligation portion of the ligation-religation reaction that topoisomerase II normally catalyzes. Topoisomerase II is an enzyme located in the nucleus that regulates DNA structure through double-strand breakage and re-ligation, therefore modulating DNA replication and transcription. Inhibition of the enzyme leads to inhibition of DNA replication and halt cell growth with an arrest of the cell cycle occurring at the G2/M phase. The mechanism by which amrubicin inhibits DNA topoisomerase II is believed to be through stabilization of the cleavable DNA–topo II complex, ending in re-ligation failure and DNA strand breakage. DNA damage triggers activation of caspase-3 and -7 and cleavage of the enzyme PARP (Poly ADP ribose polymerase), leading to apoptosis and a loss of mitochondrial membrane potential. Amrubicin, like all anthracyclines, intercalates into DNA and produces reactive oxygen free radicals via interaction with NADPH, which causes cell damage. Compared with doxorubicin, another member of the anthracycline drug class, amrubicin binds DNA with a 7-fold lower affinity and therefore, higher concentrations of amrubicin are necessary to promote DNA unwinding.

Related reactions

1 records
New reaction record
HRID 842584 reaction equation
HRID 842584As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesChemistry & industryRelated reactionsCompound notes
(7S,9S)-9-acetyl-9-amino-7-(((2S,4S,5R)-4,5-dihydroxyoxan-2-yl)oxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dioneAmrubicin(SM-5887)(7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dioneAmrubicin [INN](+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione(7S,9S)-9-acetyl-9-amino-7-(((2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dioneC25H25NO9Amrubicin [USAN:INN]

Database identifiers

CAS
110267-81-7
PubChem CID
3035016
ChEMBL
CHEMBL1186894
ChEBI
CHEBI:135779
UNII
93N13LB4Z2
Nikkaji
J361.794G
Biological Half-Life20-30 h In a study of dogs, Amrubicin plasma concentrations followed a biphasic pattern with peak concentrations observed immediately after dosing followed by α and β half-lives (t1/2) ± SD of 0.06 ± 0.01 and 2.0 ± 0.3 hours, respectively.
Metabolism/Metabolites · 1 item

The primary metabolite (amrubicinol) in rats and dogs is a product of reduction by cytoplasmic carbonyl reductase at the C-13 carbonyl group. Other enzymes participating in the metabolism of amrubicin and amrubicinol were nicotinamide adenine dinucleotide phosphate, reduced form (NADPH)–P450 reductase and nicotinamide adenine dinucleotide [phosphate] (NAD[P]H)-quinone oxidoreductase. Twelve additional metabolites were detected in vivo and in vitro in one study. Peak plasma concentrations of the active metabolite amrubicinol were observed from immediately after dosing to 1 hour after dosing. These included four aglycone metabolites, two amrubicinol glucuronides, deaminated amrubicin, and five highly polar unknown metabolites. In vitro cell growth inhibitory activity of the minor metabolites was substantially lower than that of amrubicinol. Excretion of amrubicin and its metabolites is primarily hepatobiliary. Enterohepatic recycling was demonstrated in rats.

MeSH Pharmacological ClassificationSubstances that inhibit or prevent the proliferation of NEOPLASMS.
Absorption, Distribution and Excretion · 4 items

Peak plasma concentrations of the active metabolite _amrubicinol_ were observed from immediately after administration of amrubicin to 1h after administration. Plasma concentrations of amrubicinol were low compared with amrubicin plasma concentrations. The plasma amrubicinol AUC (area under the curve) was approximately 10-fold lower than the amrubicin plasma AUC. Concentrations of amrubicinol were higher in RBCs as compared with plasma. Amrubicinol AUCs ranged from 2.5-fold to 57.9-fold higher in red blood cells (RBCs) compared to plasma. Because amrubicinol distributes itself into RBCs more than amrubicin, the concentrations of amrubicinol and amrubicin in RBCs were quite similar. The AUC of amrubicinol in RBCs was approximately twofold lower than the amrubicin RBC AUC. In one study, after repeated daily amrubicin administration, amrubicinol accumulation was observed in plasma and RBCs. On day 3, the amrubicinol plasma AUC was 1.2-fold to 6-fold higher than day 1 values; the RBC AUC was 1.2-fold to 1.7-fold higher than day 1 values. After 5 consecutive daily doses, plasma and RBC amrubicinol AUCs were 1.2-fold to 2.0-fold higher than day 1 values.

In one study, urinary excretion of amrubicin and amrubicinol after ingestion of amrubicin accounted for 2.7% to 19.6% of the administered dose. The amount of excreted amrubicinol was approximately 10-fold greater than excreted amrubicin. Excretion of amrubicin and its metabolites is primarily hepatobiliary. Enterohepatic recycling was demonstrated in rats.

Moderate volume of distribution (1.4 times total body water).

The plasma pharmacokinetics of amrubicin in cancer patients are characterized by low total clearance (22% of total liver blood flow).

Applications · 2 items

DescriptionAmrubicin is an active agent for the treatment of small-cell lung cancer (SCLC). It is a type of anthracycline analog. Anthracycline derivatives such as doxorubicin (DXR), daunorubicin (DNR) and epirubicin have been widely used for a variety of carcinomas in the clinical context. Amrubicin is structurally distinguishable from other anthracyclines by the amino group at the 9-position and its unique sugar moiety. In April 2002, Amrubicin was approved in Japan for the treatment of non-small cell lung cancer and small cell lung cancer.

UsesSynthetic anthracycline antibiotic; inhibits DNA topoisomerase II. Antineoplastic. Amrubicin is used to treat small-cell lung cancer (SCLC).

Additional notes · 1 item

DefinitionChEBI: Amrubicin is a synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol. It has a role as a topoisomerase II inhibitor, an antineoplastic agent and a prodrug. It is a quinone, a member of tetracenes, a methyl ketone, an anthracycline antibiotic and a primary amino compound.